Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its quarterly earnings results on Tuesday. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.70, Bloomberg Earnings reports.

WARNING: “Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Posts Quarterly Earnings Results, Misses Expectations By $0.70 EPS” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/protagonist-therapeutics-inc-nasdaqptgx-posts-quarterly-earnings-results-misses-expectations-by-0-70-eps/1466142.html.

In other news, insider David Y. Liu sold 3,500 shares of Protagonist Therapeutics stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $12.68, for a total value of $44,380.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

PTGX has been the subject of several recent research reports. Zacks Investment Research cut Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 12th. BTIG Research initiated coverage on Protagonist Therapeutics in a research note on Friday, July 21st. They issued a “buy” rating and a $36.00 price target for the company. Finally, BMO Capital Markets increased their price target on Protagonist Therapeutics from $34.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, May 31st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $27.60.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.